ライフサイエンスコーパス: courage

1 explores the quiet humanity behind surgical courage.

2 Of the original 2287 patients in COURAGE, 1370 (60%) had both stress perfusion imaging an

3 Patients With Amyotrophic Lateral Sclerosis (COURAGE-ALS) was a double-blind, placebo-controlled phas

4 s essay, the trailblazers whose intellectual courage and persistence has brought us to this happy pos

5 care, compassion, competence, communication, courage, and commitment.

6 edures was suboptimal; and 3) the results of COURAGE are not applicable to current clinical practice.

7 with optimal risk factor levels based on the COURAGE (Clinical Outcomes Utilizing Revascularization a

8 We obtained data from the COURAGE (Clinical Outcomes Utilizing Revascularization a

9 Of 690 patients with DM followed in the COURAGE (Clinical Outcomes Utilizing Revascularization a

10 However, the more recent COURAGE (Clinical Outcomes Utilizing Revascularization a

11 nfarction (MI) in stable CAD patients in the COURAGE (Clinical Outcomes Utilizing Revascularization a

12 er describes the medical therapy used in the COURAGE (Clinical Outcomes Utilizing Revascularization a

13 The COURAGE (Clinical Outcomes Utilizing Revascularization a

14 The COURAGE (Clinical Outcomes Utilizing Revascularization a

15 The COURAGE (Clinical Outcomes Utilizing Revascularization a

16 d trials in SIHD patients with T2DM and CKD (COURAGE [Clinical Outcomes Utilizing Revascularization a

17 Qualities of confidence, compassion, courage, commitment, communication, courtesy, and especi

18 Courage, confidence, creativity, compassion, charisma, c

19 This paper proposes a method named COURAGE (COUnty aggRegation mixup AuGmEntation) to gener

20 trol, and smoking cessation, only 18% of the COURAGE diabetes subgroup, 23% of BARI 2D patients, and

21 d with baseline increased from 55% to 77% in COURAGE, from 59% to 75% in BARI 2D, and from 34% to 42%

22 order, distress, and burden) or 2) positive (courage, humanity, justice, transcendence, temperance, a

23 rs can cultivate classic values of veracity, courage, humility, and fidelity in their research allowi

24 devastating illnesses demonstrate incredible courage in battling their disease.

25 d to each of these points, and conclude that COURAGE indeed provides relevant new information to assi

26 cularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657).

27 cularization and Aggressive Drug Evaluation (COURAGE) nuclear substudy compared the effectiveness of

28 is supplement is dedicated to the memory and courage of Hank Schueler, who fought valiantly against t

29 Among COURAGE patients assigned to OMT alone, patients' angina

30 In COURAGE patients who underwent serial MPS, adding PCI to

31 Of the 2287 COURAGE patients, 314 were enrolled in this substudy of

32 2 iPD patients and 576 healthy controls) and COURAGE-PD cohorts (7,270 iPD cases and 6,819 healthy co

33 io, OR = 1.31[1.14-1.50], p-value = 5.4e-04; COURAGE-PD OR = 1.23[1.18-1.27], p-value = 1.5e-29).

34 rist incidents that highlights fortitude and courage rather than psychological vulnerability.

35 cularization and Aggressive Drug Evaluation (COURAGE) study, which provided optimal medical therapy (

36 ill take commitment, advocacy, and political courage to advance the action agenda.

37 s not final; failure is not fatal: It is the courage to continue that counts.

38 tudent and instructor flexibility, humility, courage to engage in praxis, and willingness to learn fr

39 , reflect, and examine one's conscience; the courage to speak; and above all the willpower to act.

40 s with the highest levels of utilization pre-COURAGE trial (35% decline in the highest tertile versus

41 r association with long-term survival in the COURAGE trial (Clinical Outcomes Utilizing Revasculariza

42 ients (44.7%; 95% CI, 44.5%-44.8%) after the COURAGE trial (P < .001).

43 e (2006) and after (2008) publication of the COURAGE trial and compared those with contemporaneous ch

44 ents (43.5%; 95% CI, 43.2%-43.7%) before the COURAGE trial and in 131,188 patients (44.7%; 95% CI, 44

45 intensively to both treatment groups in the COURAGE trial by nurse case managers with treatment prot

46 An in-depth analysis of the COURAGE trial design and execution is provided.

47 Optimal medical therapy in the COURAGE trial provides an effective model for secondary

48 The COURAGE trial tested multiple lifestyle and pharmacologi

49 discharge following PCI before and after the COURAGE trial was 63.5% (95% CI, 63.3%-63.7%) and 66.0%

50 before [37.1%] and 293,795 after [62.9%] the COURAGE trial) meeting study criteria, OMT was used in 2

51 After the publication of the COURAGE trial, PCI volume for SIHD declined by 25% (P<0.

52 In the COURAGE trial, the addition of percutaneous coronary int

53 Among stable CAD patients in the COURAGE trial, the presence of MetS identified increased

54 is in 2,193 men and women with SIHD from the COURAGE trial.

55 rge, before and after the publication of the COURAGE trial.

56 ctice or whether its use increased after the COURAGE trial.

57 e practice patterns after publication of the COURAGE trial.

58 tes OMT, based largely on the results of the COURAGE trial.

59 in PCI for SIHD after the publication of the COURAGE trial.

60 CI for SIHD preceding the publication of the COURAGE trial.

61 CAD meeting 7 risk factor goals based on the COURAGE trial: 1) aspirin use; 2) systolic blood pressur

62 cularization and Aggressive Drug Evaluation (COURAGE) trial reignited the controversy of the benefit

63 cularization and Aggressive Drug Evaluation (COURAGE) trial, some patients with stable ischemic heart

64 cularization and Aggressive Drug Evaluation (COURAGE) trial, which will be the largest of the studies

65 cularization and Aggressive Drug Evaluation (COURAGE) trial.

66 COURAGE was not designed to evaluate changes in the freq

67 Generating the energy, insight, and courage we need to get to "total quality" may require th